{ "company": "IQVIA Holdings", "ticker": "IQV", "period": { "from": "2026-03-02", "to": "2026-04-01", "days": 30 }, "sentiment_breakdown": { "positive": 32, "negative": 7, "neutral": 41 }, "synthesis": { "executive_summary": "**Executive Summary: IQVIA Holdings (IQV) Sentiment Analysis**\n\nSentiment analysis for IQVIA Holdings (IQV) between March 2 and April 1, 2026, reveals a net positive outlook, with 32 positive mentions significantly outweighing 7 negative items amidst 41 neutral discussions out of 80 total. Key drivers for this positive sentiment include IQVIA's robust business model, leveraging AI innovation and vast datasets in clinical research and R&D solutions, which is seen as a source of durable demand. Analyst upgrades, notably Barclays' \"overweight\" rating with a $210 target price and RBC Capital's initiation of coverage, underscore investor confidence in the company's strategic positioning and strong execution within the healthcare intelligence sector.\n\nConversely, negative sentiment largely stemmed from technical indicators, specifically a \"Death Cross\" formation signaling potential bearish momentum, and consistent reports of IQV's stock underperforming major indices and competitors. A notable internal concern emerged from employee feedback on social media, highlighting potential operational challenges related to high workload and management issues for clinical research associates. While the overall sentiment remains favorable due to strategic strengths and market positioning, these technical and internal factors warrant close monitoring for potential impact on future performance.", "key_findings": [ "✓ Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution", "✓ IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities", "✓ IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth", "✗ IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead", "✗ Fired from IQVIA. (I'm a CRA in US)", "✗ Is IQVIA Holdings Stock Underperforming the Nasdaq?" ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution", "date": "2026-03-31", "source": "alpha_vantage", "score": 0.991 }, { "title": "IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.9 }, { "title": "IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth", "date": "2026-03-10", "source": "news", "score": 0.856 }, { "title": "Healthcare Consulting Services Market Size to Hit USD 77.19 Billion by 2035 Amid Digital Transformation and Value-Based Care Acceleration – SNS Insider", "date": "2026-03-03", "source": "news", "score": 0.802 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-03-30", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-03-17", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. (IQV) offers impressive upside despite AI-linked threats", "date": "2026-03-18", "source": "alpha_vantage", "score": 0.684 }, { "title": "IQVIA Holdings Inc. $IQV Shares Acquired by Diversified Trust Co.", "date": "2026-03-24", "source": "alpha_vantage", "score": 0.67 }, { "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.66 }, { "title": "CIBC Private Wealth Group LLC Sells 14,961 Shares of IQVIA Holdings Inc. $IQV", "date": "2026-03-18", "source": "alpha_vantage", "score": 0.66 } ], "top_negative": [ { "title": "IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead", "date": "2026-03-25", "source": "alpha_vantage", "score": -0.599 }, { "title": "Fired from IQVIA. (I'm a CRA in US)", "date": "2026-03-12", "source": "reddit", "score": -0.557 }, { "title": "Is IQVIA Holdings Stock Underperforming the Nasdaq?", "date": "2026-03-10", "source": "news", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock underperforms Friday when compared to competitors", "date": "2026-03-27", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA BioTech Layoffs", "date": "2026-03-02", "source": "reddit", "score": -0.2 }, { "title": "IQVIA Holdings Inc stock faces pressure after Q4 earnings beat amid high volume trading on NYSE", "date": "2026-03-21", "source": "alpha_vantage", "score": -0.096 } ], "raw_data": { "total_items": 80, "items": [ { "source": "news", "source_name": "Yahoo Entertainment", "title": "TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0f826ad2-de99-47c1-afef-222a2c734ee3", "date": "2026-03-24", "published_at": "2026-03-24T14:43:11Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth", "description": "IQVIA Holdings Inc. (NYSE:IQV) is one of the 11 Best Affordable Growth Stocks to Buy Now. On March 3, analysts at RBC Capital initiated coverage of IQVIA...", "url": "https://finance.yahoo.com/news/iqvia-holdings-inc-iqv-advances-183828418.html", "date": "2026-03-10", "published_at": "2026-03-10T18:38:28Z", "sentiment": { "label": "positive", "score": 0.856, "confidence": 0.86 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Is IQVIA Holdings Stock Underperforming the Nasdaq?", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_8e570186-ab6b-4559-8f61-50c8109d77b1", "date": "2026-03-10", "published_at": "2026-03-10T14:01:35Z", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Healthcare Consulting Services Market Size to Hit USD 77.19 Billion by 2035 Amid Digital Transformation and Value-Based Care Acceleration – SNS Insider", "description": "Rising regulatory complexity, AI-driven analytics adoption, and operational efficiency mandates propel global market at 9.37% CAGR through 2035 Rising regulatory complexity, AI-driven analytics adoption, and operational efficiency mandates propel global marke…", "url": "https://www.globenewswire.com/news-release/2026/03/03/3248121/0/en/Healthcare-Consulting-Services-Market-Size-to-Hit-USD-77-19-Billion-by-2035-Amid-Digital-Transformation-and-Value-Based-Care-Acceleration-SNS-Insider.html", "date": "2026-03-03", "published_at": "2026-03-03T11:00:00Z", "sentiment": { "label": "positive", "score": 0.802, "confidence": 0.8 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Analysts at Mizuho Remain Bullish on IQVIA (IQV) Following Q4 Results", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_5566d0c3-c947-4ecf-ac65-7aad1e2f9d1c", "date": "2026-03-02", "published_at": "2026-03-02T20:36:33Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution", "url": "https://www.morningstar.com/company-reports/1463752-positive-outlook-for-narrow-moat-iqvia-supported-by-durable-demand-ai-innovation-and-execution", "date": "2026-03-31", "summary": "Iqvia, formed from the merger of Quintiles and IMS Health, is a leader in contract research organizations and life sciences data. The company benefits from durable demand, AI innovation, and strong execution. This positive outlook is supported by its strong position in real-world evidence and robust business strategy.", "sentiment_score": 0.480525, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.991, "confidence": 0.99 } }, { "source": "alpha_vantage", "title": "Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot", "url": "https://www.stocktitan.net/sec-filings/PGNY/pre-14a-progyny-inc-preliminary-proxy-statement-55f7fc59e4a7.html", "date": "2026-03-31", "summary": "Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance b", "sentiment_score": 0.027702, "sentiment_label": "Neutral", "relevance_score": 0.661968, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-rises-tuesday-still-underperforms-market-7ed58b48-8be52711e922?gaa_at=eafs&gaa_n=AWEtsqdkg4GWRubztghb9qzn9GPls8JncW-HR4U_W01zwVLK23I93XDLDG-g&gaa_ts=69ccb2bd&gaa_sig=IcMs0idqDaoE01uQbOwzExZGjbPDOvwQa3Ca17tVo_6gfR9Kg6ehBx3A904friBl3eRRLJGpfcyjZIZcE5ahEw%3D%3D", "date": "2026-03-31", "summary": "IQVIA Holdings Inc. (IQV) saw its stock rise by 2.64% on Tuesday, closing at $170.54. Despite this gain, the company's performance underperformed the broader market, which experienced a favorable trading session with the S&P 500 Index and Dow Jones Industrial Average rising more significantly. This marked the second consecutive day of gains for IQVIA stock.", "sentiment_score": 0.211183, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "195,165 Shares in IQVIA Holdings Inc. $IQV Purchased by Vaughan Nelson Investment Management L.P.", "url": "https://www.marketbeat.com/instant-alerts/filing-195165-shares-in-iqvia-holdings-inc-iqv-purchased-by-vaughan-nelson-investment-management-lp-2026-03-31/", "date": "2026-03-31", "summary": "Vaughan Nelson Investment Management L.P. recently purchased 195,165 shares of IQVIA Holdings Inc. (NYSE:IQV) stock, valued at approximately $43.99 million, representing a new stake in the company. Other institutional investors have also adjusted their holdings in IQVIA. Analysts generally rate IQVIA as a \"Buy\" with a consensus price target of $229.13, following strong Q4 earnings where the company beat estimates and provided positive FY2026 guidance.", "sentiment_score": 0.480439, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-09d2bbde-8f34dadb5fa6?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcwfreGoQnhWhu6rQxA27XM3I6Fh5Q6TT5gzXY2xERyhqp26ign8Q-m&gaa_ts=69cb6f3f&gaa_sig=3F9k_D6LL2qrSQRkz_tpnlCxCPM5elKjxlC1J_IbbfHeEq018I3lGg1tLkrMYLFG5b_ptBK0THlNCPDUb0Da6Q%3D%3D", "date": "2026-03-30", "summary": "Shares of IQVIA Holdings Inc. (IQV) rose 1.41% to $166.16 on Monday, outperforming the broader market. This occurred during a mixed trading session where the Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index declined. The company's stock is currently 32.74% below its 52-week high.", "sentiment_score": 0.395428, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Behavioral Patterns of IQV and Institutional Flows - Stock Traders Daily", "url": "https://news.stocktradersdaily.com/news_release/98/Behavioral_Patterns_of_IQV_and_Institutional_Flows_033026075201_1774914721.html", "date": "2026-03-30", "summary": "This article analyzes Iqvia Holdings Inc. (NYSE: IQV) using AI models to identify behavioral patterns and institutional trading flows. It suggests a weak near and mid-term sentiment, potentially challenging a long-term positive outlook, and outlines specific trading strategies (position, momentum, and risk hedging) with detailed entry, target, and stop-loss levels based on different risk profiles. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the s", "sentiment_score": -0.241446, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc (IQV) Shares Gap Down to $163.85 on Mar 30", "url": "https://www.gurufocus.com/news/8756831/iqvia-holdings-inc-iqv-shares-gap-down-to-16385-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "IQVIA Holdings Inc (IQV) shares fell 3.28% in mid-day trading on March 30, reaching an intraday low of $162.36 before closing at $163.85. This puts the stock significantly below its 52-week high, while analysts maintain an \"Outperform\" rating with an average target price implying a 44.47% upside. GuruFocus' estimated fair value (GF Value) suggests an even greater potential upside of 60.57%.", "sentiment_score": -0.217551, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating", "url": "https://www.moomoo.com/news/post/67626416/truist-financial-maintains-iqvia-holdings-iqvus-with-buy-rating", "date": "2026-03-30", "summary": "Truist Financial has reaffirmed its Buy rating on IQVIA Holdings (IQV.US). This indicates a continued positive outlook from the financial institution regarding the company's stock performance.", "sentiment_score": 0.423837, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-buys-26161-shares-of-iqvia-holdings-inc-iqv-2026-03-30/", "date": "2026-03-30", "summary": "SG Americas Securities LLC increased its stake in IQVIA Holdings Inc. by 108.8% in Q4, acquiring an additional 26,161 shares, bringing its total to 50,206 shares valued at $11.32 million. IQVIA reported strong Q4 earnings, beating analyst estimates with EPS of $3.42 and revenue of $4.36 billion, and provided positive FY2026 guidance. Wall Street analysts maintain a \"Buy\" consensus rating for IQVIA, with an average target price of $229.13.", "sentiment_score": 0.447253, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "GSK’s hepatitis B drug accepted for China regulatory review", "url": "https://www.investing.com/news/company-news/gsks-hepatitis-b-drug-accepted-for-china-regulatory-review-93CH-4586716", "date": "2026-03-30", "summary": "GSK announced that China's National Medical Products Administration has accepted a new drug application for bepirovirsen, its investigational treatment for chronic hepatitis B. This submission is supported by positive Phase III clinical trial results showing statistically significant functional cure rates. The drug aims to address the significant health burden of chronic hepatitis B, which affects millions in China and worldwide.", "sentiment_score": 0.238147, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.646384, "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-purchases-9480-shares-of-iqvia-holdings-inc-iqv-2026-03-28/", "date": "2026-03-28", "summary": "Wealth Enhancement Advisory Services LLC has increased its stake in IQVIA Holdings Inc. by 35.8%, acquiring an additional 9,480 shares and bringing its total holdings to 35,960 shares valued at $8.674 million. IQVIA currently holds a consensus \"Buy\" rating with a price target of $229.13 and recently surpassed quarterly earnings expectations. The company also issued a positive FY2026 EPS guidance of $12.55–$12.85.", "sentiment_score": 0.496848, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Eagle Rock Investment Company LLC Buys 14,084 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-eagle-rock-investment-company-llc-buys-14084-shares-of-iqvia-holdings-inc-iqv-2026-03-28/", "date": "2026-03-28", "summary": "Eagle Rock Investment Company LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.4% in the fourth quarter, acquiring an additional 14,084 shares and bringing their total holdings to 60,416 shares valued at $13.62 million. Other institutional investors also adjusted their positions in IQV. Several Wall Street analysts have issued \"Buy\" or \"Overweight\" ratings for IQVIA, with an average price target of $229.13.", "sentiment_score": 0.410436, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213", "url": "http://www.msn.com/en-us/money/topstocks/td-cowen-upgrades-iqvia-iqv-to-buy-and-raises-price-target-to-213/ar-AA1ZiJKO?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-27", "summary": "TD Cowen has upgraded IQVIA (IQV) to a \"buy\" rating and increased its price target to $213. This upgrade reflects a positive outlook on the company's financial prospects and market position. The revised price target suggests a significant upside potential for IQVIA's stock.", "sentiment_score": 0.404529, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock underperforms Friday when compared to competitors", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-friday-when-compared-to-competitors-8ead1f3c-074eaa0da08e?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqejRuGIxbWxjCCr0y-0qvJaoLYLIb4-x_16oIuyk6D8Y2YPo559z5ak&gaa_ts=69c773b6&gaa_sig=rEqRwe-25x1IVNKLzUTPbdAcF4Bhf3EAyc7pfv1MJr6dzqL8HcFyWwCUhUCu8xdMcJ3JSxRIJX_o-0CVFfsgMA%3D%3D", "date": "2026-03-27", "summary": "IQVIA Holdings Inc. (IQV) stock fell 3.28% on Friday, closing at $163.85, a day when the broader market also experienced declines with the S&P 500 down 1.67% and the Dow Jones Industrial Average down 1.73%. This performance places IQVIA Holdings Inc. 33.68% below its 52-week high of $247.05, reached on January 9th. The article highlights the stock's underperformance relative to major indices.", "sentiment_score": -0.418814, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "A Look At IQVIA Holdings (IQV) Valuation After The IQVIA.ai Launch With NVIDIA And Analyst Upgrades", "url": "https://www.sahmcapital.com/news/content/a-look-at-iqvia-holdings-iqv-valuation-after-the-iqviaai-launch-with-nvidia-and-analyst-upgrades-2026-03-28", "date": "2026-03-27", "summary": "IQVIA Holdings (IQV) recently launched IQVIA.ai in collaboration with NVIDIA, aiming to integrate AI into life sciences workflows. Despite this launch and analyst upgrades, the stock has seen declines over 1 day, 90 days, and 1 year, trading at $163.85. Simply Wall St's \"Most Popular Narrative\" suggests the stock is 34.5% undervalued with a fair value of $250 per share, attributing this to future earnings power and AI-driven efficiency, though it acknowledges potential challenges from pricing pr", "sentiment_score": 0.278256, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Vanguard (IQV) Amendment 13G/A: reports 0 shares after realignment", "url": "https://www.stocktitan.net/sec-filings/IQV/schedule-13g-a-iqvia-holdings-inc-amended-passive-investment-disclosu-ca3ac4657526.html", "date": "2026-03-27", "summary": "The Vanguard Group filed an Amendment No. 11 to a Schedule 13G/A for IQVIA Holdings Inc., reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. This change is due to an internal realignment completed on January 12, 2026, where certain subsidiaries will now report beneficial ownership separately. The filing confirms Vanguard no longer holds, or is deemed to hold, beneficial ownership over these securities.", "sentiment_score": 0.043329, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Invera Wealth Advisors, LLC's IQVIA Holdings Inc(IQV) Holding History", "url": "https://www.gurufocus.com/guru-portfolio/Invera%20Wealth%20Advisors,%20LLC/IQV", "date": "2026-03-27", "summary": "This article details Invera Wealth Advisors, LLC's historical holdings in IQVIA Holdings Inc (IQV) as of December 31, 2025. It shows that Invera Wealth Advisors holds 10,537 shares valued at $2.38 million, representing 1.5% of their portfolio. The firm has made 3 purchases and 5 sales of IQV shares since Q4 2023, resulting in an estimated loss of -15.07% on their current holdings.", "sentiment_score": -0.107506, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-business-model-strength-and-analyst-upgrades/69004027", "date": "2026-03-27", "summary": "IQVIA Holdings Inc (IQV) is highlighted as a global leader in healthcare intelligence, benefiting from a recent Barclays upgrade to overweight with a $210 target price. The company's strong business model leverages vast datasets and AI-driven insights in clinical research and R&D solutions, positioning it well amid rising demand for real-world evidence and personalized medicine. North American investors are encouraged to consider IQV for its resilient healthcare exposure and predictable cash flo", "sentiment_score": 0.417792, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.9, "confidence": 0.9 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of \"Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/iqvia-holdings-inc-nyseiqv-given-average-rating-of-buy-by-brokerages-2026-03-27/", "date": "2026-03-27", "summary": "IQVIA Holdings Inc. (NYSE:IQV) has received an average \"Buy\" rating from seventeen brokerages, with an average 12-month price target of $229.13. The medical research company recently exceeded quarterly earnings and revenue estimates and set a positive FY 2026 EPS guidance. Institutional investors hold a significant stake in IQVIA, with shares currently trading at $169.05, representing a market capitalization of approximately $28.7 billion.", "sentiment_score": 0.434098, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/IQV/page-3.html", "date": "2026-03-26", "summary": "This page provides comprehensive access to IQVIA Holdings Inc. (IQV) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent insider transactions where executives received performance-based shares and disposed of others, often to cover tax obligations. The platform also offers AI-powered summaries of these filings to help investors understand key corporate developments and financial information.", "sentiment_score": 0.007415, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips", "url": "https://m.investing.com/news/transcripts/earnings-call-transcript-optimizerx-q4-2025-earnings-beat-forecasts-stock-dips-93CH-4581514?ampMode=1", "date": "2026-03-26", "summary": "OptimizeRx (OPRX) reported strong financial results for Q4 2025, with EPS of $0.51 and revenue of $32.2 million, both exceeding forecasts. Despite the earnings beat and a record gross margin of 74.8%, the stock declined 14.36% in after-hours trading, potentially due to broader market conditions or investor concerns about future normalized margins. The company provided 2026 guidance with revenue between $109 million-$114 million and adjusted EBITDA between $21 million-$25 million, reflecting a mo", "sentiment_score": 0.107723, "sentiment_label": "Neutral", "relevance_score": 0.627308, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Is IQVIA.ai’s NVIDIA‑Powered Platform Altering The Investment Case For IQVIA Holdings (IQV)?", "url": "https://www.sahmcapital.com/news/content/is-iqviaais-nvidiapowered-platform-altering-the-investment-case-for-iqvia-holdings-iqv-2026-03-24", "date": "2026-03-25", "summary": "IQVIA Holdings recently launched IQVIA.ai, an NVIDIA-powered AI platform designed to embed healthcare-grade AI into life sciences workflows. This platform, along with an expanded partnership with Salesforce, aims to strengthen IQVIA's data and AI integration within pharmaceutical processes and reinforce switching costs. While the new platform offers AI-enabled differentiation, analysts note that intense CRO competition and pricing pressures remain significant risks to IQVIA's investment narrativ", "sentiment_score": 0.285726, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead", "url": "https://www.marketsmojo.com/news/stocks-in-action/iqvia-holdings-forms-death-cross-signaling-potential-bearish-trend-ahead-3911291", "date": "2026-03-25", "summary": "IQVIA Holdings, Inc. has experienced a \"Death Cross\" technical event, where its short-term moving average fell below its long-term moving average, signaling potential bearish momentum. The stock has significantly underperformed the S&P 500 over the past year and year-to-date, indicating a challenging market position and potential for further declines.", "sentiment_score": -0.648567, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. $IQV Stock Position Decreased by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stock-position-decreased-by-assenagon-asset-management-sa-2026-03-25/", "date": "2026-03-25", "summary": "Assenagon Asset Management S.A. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.7% during the fourth quarter, selling 21,374 shares. Despite this, other institutional investors increased their positions in IQVIA. The medical research company has an average \"Buy\" rating from analysts with an average price target of $229.13, and recently beat earnings estimates for the latest quarter.", "sentiment_score": 0.12639, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "ICON, Advarra Partner on Connected Site Network Model", "url": "https://www.contractpharma.com/breaking-news/icon-advarra-partner-on-connected-site-network-model/", "date": "2026-03-24", "summary": "ICON plc and Advarra have formed a strategic partnership to develop a \"research-ready\" connected site network model for clinical trials. This collaboration aims to integrate ICON’s global clinical trial services with Advarra’s site systems, including CTMSs, eISF, and eSource, to streamline operations. The goal is to reduce administrative burdens, accelerate study startup, and improve overall clinical trial participation and efficiency by leveraging Advarra's operational intelligence platform.", "sentiment_score": 0.267779, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.63925, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213", "url": "https://www.msn.com/en-us/money/topstocks/td-cowen-upgrades-iqvia-iqv-to-buy-and-raises-price-target-to-213/ar-AA1ZiJKO?ocid=finance-verthp-feeds", "date": "2026-03-24", "summary": "TD Cowen has upgraded its rating for IQVIA (IQV) from market perform to buy. The firm also increased its price target for IQV shares to $213. This indicates a positive outlook on the company's future performance by TD Cowen.", "sentiment_score": 0.443558, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213", "url": "https://www.insidermonkey.com/blog/td-cowen-upgrades-iqvia-iqv-to-buy-and-raises-price-target-to-213-1723124/", "date": "2026-03-24", "summary": "TD Cowen has upgraded IQVIA Holdings Inc. (IQV) to Buy from Hold and increased its price target to $213, citing an attractive risk-reward opportunity after a 24% share price decline. Analysts believe IQVIA will remain resilient against AI-driven revenue headwinds, expecting savings from AI to be reinvested into research. This upgrade follows a similar move by Barclays, which also upgraded IQV to Overweight with a $210 price target.", "sentiment_score": 0.603437, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Community Trust & Investment Co. Reduces Stock Holdings in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-community-trust-investment-co-reduces-stock-holdings-in-iqvia-holdings-inc-iqv-2026-03-24/", "date": "2026-03-24", "summary": "Community Trust & Investment Co. significantly reduced its stake in IQVIA Holdings Inc. by 7.9% in the fourth quarter, now owning 100,312 shares valued at $22.611 million. Despite this reduction, IQVIA demonstrated strong financial performance, exceeding Q4 earnings and revenue expectations and receiving broad analyst support with a \"Buy\" rating and an average target price of $229.13. Several other hedge funds, however, increased their positions in the medical research company during the same pe", "sentiment_score": 0.215808, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. $IQV Shares Acquired by Diversified Trust Co.", "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-shares-acquired-by-diversified-trust-co-2026-03-24/", "date": "2026-03-24", "summary": "Diversified Trust Co. has increased its stake in IQVIA Holdings Inc. by 14.8% to 48,876 shares, now valued at $11.017 million. Institutional investors collectively own about 89.62% of the company's stock. Analysts currently hold a \"Buy\" rating for IQVIA, with an average price target of $229.13, following the company's recent strong Q4 earnings report where it surpassed revenue and EPS estimates.", "sentiment_score": 0.419693, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings, Inc. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators", "url": "https://www.marketsmojo.com/news/stocks-in-action/iqvia-holdings-inc-technical-trend-shifts-from-sideways-to-mildly-bullish-despite-stock-decline-3908487", "date": "2026-03-24", "summary": "IQVIA Holdings, Inc. has seen a revision in its stock evaluation, with its current price at $166.07 after experiencing significant volatility over the past year. Technical indicators like MACD, RSI, and Bollinger Bands present a mixed outlook, with some indicating bearish trends while others are mildly bullish. The company's stock performance has consistently underperformed the S&P 500, highlighting challenges in a competitive market.", "sentiment_score": -0.285369, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Nordea Investment Management AB Sells 1,600,906 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-nordea-investment-management-ab-sells-1600906-shares-of-iqvia-holdings-inc-iqv-2026-03-23/", "date": "2026-03-23", "summary": "Nordea Investment Management AB significantly reduced its stake in IQVIA Holdings Inc. by selling 1,600,906 shares in the fourth quarter, retaining 713,313 shares valued at $161.5 million. Despite this, Wall Street analysts maintain a positive outlook with a consensus \"Buy\" rating and an average price target of $229.13. IQVIA recently surpassed quarterly revenue and EPS estimates, showing 10.3% year-over-year revenue growth and providing strong FY2026 EPS guidance.", "sentiment_score": 0.133092, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "TD Cowen Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $213", "url": "https://www.moomoo.com/news/post/67229988/td-cowen-maintains-iqvia-holdings-iqvus-with-buy-rating-raises", "date": "2026-03-23", "summary": "TD Cowen has reiterated its Buy rating on IQVIA Holdings (IQV.US) and increased its price target to $213. This indicates continued confidence in the company's performance and future growth prospects from the analyst firm.", "sentiment_score": 0.48615, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/IQV/page-6.html", "date": "2026-03-23", "summary": "This article provides access to IQVIA Holdings Inc. (IQV) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how these documents offer insights into the company's financial health, governance, and operations. The platform also utilizes AI-powered summaries to interpret lengthy filings for investors.", "sentiment_score": 0.021466, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock faces earnings anticipation amid healthcare analytics boom", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-faces-earnings-anticipation-amid-healthcare/68957025", "date": "2026-03-22", "summary": "IQVIA Holdings Inc. (ISIN: US46266C1053) is drawing investor attention ahead of upcoming earnings reports, with analysts projecting steady EPS growth in the healthcare analytics sector due to increasing demand for data-driven drug development. The company, a leader in clinical research and real-world evidence, is seen as a resilient investment for DACH investors, less exposed to European regulatory volatility. Its integrated model and strategic acquisitions in AI are fueling expansion and strong", "sentiment_score": 0.494505, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "A Look At IQVIA Holdings (IQV) Valuation After The IQVIA.ai Launch With NVIDIA", "url": "https://www.sahmcapital.com/news/content/a-look-at-iqvia-holdings-iqv-valuation-after-the-iqviaai-launch-with-nvidia-2026-03-20", "date": "2026-03-21", "summary": "IQVIA Holdings' (IQV) recent launch of IQVIA.ai, an agentic AI platform built with NVIDIA tools, has drawn attention, despite the stock's year-to-date decline. The article suggests IQVIA is currently undervalued, with a fair value estimated at $250, due to its proprietary platforms and strategic collaborations. However, risks like pressure on CRO pricing and higher leverage are noted as potential limitations to margin improvement.", "sentiment_score": 0.274394, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock surges in volume on NYSE amid Q4 earnings beat and FY2026 guidance", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-surges-in-volume-on-nyse-amid-q4-earnings-beat/68949508", "date": "2026-03-21", "summary": "IQVIA Holdings Inc (ISIN: US46266C1053) experienced a significant surge in trading volume on the NYSE after reporting Q4 2025 earnings that surpassed expectations. Despite beating on EPS and revenue, the stock saw a slight dip due to cautious FY2026 guidance and identified risks. The article highlights the company's strong focus on AI-driven healthcare analytics, increasing demand from pharmaceutical clients, and divergent sentiments among institutional investors.", "sentiment_score": 0.286874, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc stock faces pressure after Q4 earnings beat amid high volume trading on NYSE", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/iqvia-holdings-inc-stock-faces-pressure-after-q4-earnings-beat-amid-high/68948992", "date": "2026-03-21", "summary": "IQVIA Holdings Inc (US46266C1053) saw its shares dip 0.24% on the NYSE despite exceeding Q4 2025 earnings estimates, with trading volume surging 157% to $570 million. Investors are weighing the strong Q4 results against the company's FY2026 guidance, its AI strategy, and looming macroeconomic risks. German-speaking (DACH) investors are particularly interested due to IQVIA's significant European market presence and growth potential in healthcare data and AI-driven analytics.", "sentiment_score": 0.048739, "sentiment_label": "Neutral", "relevance_score": 0.33063, "sentiment": { "label": "negative", "score": -0.096, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "A Look At IQVIA Holdings (IQV) Valuation After The IQVIA.ai Launch With NVIDIA", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/a-look-at-iqvia-holdings-iqv-valuation-after-the-iqviaai-lau", "date": "2026-03-20", "summary": "IQVIA Holdings (IQV) has launched IQVIA.ai, an agentic AI platform built with NVIDIA tools for life sciences. Despite this, the stock's share price has fallen year-to-date and trades below analyst targets and its estimated intrinsic value of $250, suggesting it may be undervalued. While the AI platform offers potential for long-term growth and market share capture, risks such as pressure on CRO pricing and IQVIA's higher leverage could impact margin improvement and leave it vulnerable if demand ", "sentiment_score": 0.284969, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer", "url": "https://sg.finance.yahoo.com/news/aquestive-therapeutics-announces-role-lori-110000550.html", "date": "2026-03-20", "summary": "Aquestive Therapeutics has announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026. He succeeds Lori J. Braender, who will transition to a non-executive role as Corporate Secretary. Zalewski brings extensive experience in life sciences law and has previously served as a Partner at Day Pitney LLP.", "sentiment_score": 0.110932, "sentiment_label": "Neutral", "relevance_score": 0.623552, "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Assessing Veeva Systems (VEEV) Valuation After AOP Health Expands Onto Its Unified Cloud Platforms", "url": "https://www.sahmcapital.com/news/content/assessing-veeva-systems-veev-valuation-after-aop-health-expands-onto-its-unified-cloud-platforms-2026-03-21", "date": "2026-03-20", "summary": "Veeva Systems (VEEV) recently saw AOP Health expand its operations onto its cloud platforms, showcasing the deep integration of Veeva's software. Despite this positive news, Veeva's stock has seen a significant decline over the past year, though it shows a slight recovery in the last week. The article discusses Veeva's valuation, noting it's considered undervalued by a key narrative due to potential market expansion and revenue growth, but its P/E ratio suggests the market already factors in opt", "sentiment_score": 0.240739, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.612321, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "(IQV) Movement Within Algorithmic Entry Frameworks", "url": "https://news.stocktradersdaily.com/news_release/34/IQV_Movement_Within_Algorithmic_Entry_Frameworks_031926064402_1773960242.html", "date": "2026-03-19", "summary": "Iqvia Holdings Inc. (IQV) is showing neutral near and mid-term readings but maintains a long-term positive bias according to algorithmic analysis. The article presents various trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. Multi-timeframe analysis indicates strong long-term support and resistance signals despite current neutral sentiment.", "sentiment_score": 0.042532, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Leerink Conference: $30 Target Price From AI Data Moat", "url": "https://www.tikr.com/blog/iqvia-leerink-conference-30-target-price-from-ai-data-moat", "date": "2026-03-19", "summary": "IQVIA Holdings Inc. presented at the Leerink Global Healthcare Conference, emphasizing its position as an AI company in the life sciences sector. CEO Ari Bousbib countered the bear thesis by highlighting IQVIA's proprietary data, which constitutes about 70% of all data used by the pharma industry, as a critical component for effective AI in drug development. The company has partnered with NVIDIA to deploy over 150 custom AI agents and forecasts a $301 price target driven by its data moat, strate", "sentiment_score": 0.474698, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Medpace Holdings Inc Stock (ISIN: US5840631062) Faces Mixed Analyst Signals Amid Strong CRO Demand", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/medpace-holdings-inc-stock-isin-us5840631062-faces-mixed-analyst/68850576", "date": "2026-03-19", "summary": "Medpace Holdings Inc (MEDP) is experiencing robust growth driven by strong demand in the contract research organization sector, with its stock trading around $605 after an 82% year-to-date gain. Despite strong earnings and guidance, the company faces mixed analyst signals and insider selling, leading to a \"Hold\" consensus with varying price targets. European investors are showing interest in US CROs like Medpace due to outsourcing demand from stringent clinical regulations.", "sentiment_score": 0.116422, "sentiment_label": "Neutral", "relevance_score": 0.634728, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. (IQV) offers impressive upside despite AI-linked threats", "url": "http://www.msn.com/en-us/money/topstocks/iqvia-holdings-inc-iqv-offers-impressive-upside-despite-ai-linked-threats/ar-AA1WZRo1?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-18", "summary": "This article analyzes the investment potential of IQVIA Holdings Inc. (IQV), emphasizing its strong fundamentals and market position despite perceived threats from AI advancements. It highlights IQV's consistent organic growth, dividend payments, and share buybacks, suggesting that the stock is undervalued and poised for significant upside. The analysis also touches on IQV's performance metrics and its strategic moves to integrate AI, positioning it favorably in the evolving healthcare technolog", "sentiment_score": 0.637228, "sentiment_label": "Bullish", "relevance_score": 0.9745, "sentiment": { "label": "positive", "score": 0.684, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights", "url": "https://www.manilatimes.net/2026/03/18/tmt-newswire/globenewswire/onemednet-and-navidence-announce-strategic-collaboration-empowering-pharma-with-precision-real-world-data-insights/2302790", "date": "2026-03-18", "summary": "OneMedNet and Navidence have partnered to enhance the utilization of Real-World Data (RWD) in the pharmaceutical industry. This collaboration integrates Navidence's Computable Operational Definitions (CODefs) with OneMedNet's iRWD™ platform, aiming to provide pharmaceutical companies with faster, more precise, and usable data for research, regulatory submissions, and AI model training. The partnership is expected to drive efficiency, reduce costs, and improve regulatory compliance in real-world ", "sentiment_score": 0.258146, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.577737, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "CIBC Private Wealth Group LLC Sells 14,961 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-cibc-private-wealth-group-llc-sells-14961-shares-of-iqvia-holdings-inc-iqv-2026-03-18/", "date": "2026-03-18", "summary": "CIBC Private Wealth Group LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.1% in the third quarter, selling 14,961 shares. Despite this, the firm still holds over 1.3 million shares valued at approximately $250.475 million. IQVIA recently exceeded quarterly earnings and revenue estimates, provided positive FY2026 guidance, and maintains an average \"Buy\" rating from analysts.", "sentiment_score": 0.311444, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Is IQVIA’s New NVIDIA-Powered IQVIA.ai Platform (IQV) Deepening a Durable AI Moat or Raising Complexity?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/is-iqvias-new-nvidia-powered-iqviaai-platform-iqv-deepening/amp", "date": "2026-03-18", "summary": "IQVIA Holdings unveiled IQVIA.ai, an NVIDIA-powered AI platform, aiming to embed healthcare-grade AI into life sciences workflows and deepen its differentiation. While this reinforces IQVIA's AI-driven strategy, investors must consider the company's high leverage and data privacy exposure amidst its 2026 revenue guidance of US$17,150 million to US$17,350 million. The success of IQVIA.ai in supporting this outlook and mitigating risks, versus raising new questions about execution and capital inte", "sentiment_score": 0.132094, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-a5804cff-d6c27d39e657?gaa_at=eafs&gaa_n=AWEtsqc0sHgZLzSJb-B61aesn5_YBJjqGO-Md5_dVwwRw1uuaL8h_goMf992&gaa_ts=69b9f755&gaa_sig=GD8yv9LeOoFqaUfwhqpZ_3qiTckRG6ijEpzoJHIU7xN5UHJiAV11I51venfHTVumsOiXoseQdSPeU7n2XFGpGA%3D%3D", "date": "2026-03-17", "summary": "Shares of IQVIA Holdings Inc. (IQV) rose 2.15% to $168.43, outperforming competitors and the broader market on a strong trading day. This marks the third consecutive day of gains for the stock. The S&P 500 Index and Dow Jones Industrial Average also saw gains.", "sentiment_score": 0.420062, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Is IQVIA’s New NVIDIA-Powered IQVIA.ai Platform (IQV) Deepening a Durable AI Moat or Raising Complexity?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/is-iqvias-new-nvidia-powered-iqviaai-platform-iqv-deepening", "date": "2026-03-17", "summary": "IQVIA Holdings Inc. has launched IQVIA.ai, an NVIDIA-powered AI platform designed to embed healthcare-grade AI into life sciences workflows, aiming to deepen its AI-driven differentiation. While this platform could reinforce IQVIA's investment narrative, it also introduces questions regarding execution, capital intensity, and the return on AI investments, especially considering the company's high leverage and data privacy exposure. Analysts hold differing views on its impact, with some more caut", "sentiment_score": 0.296921, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Cinctive Capital Management LP Makes New $2.51 Million Investment in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-cinctive-capital-management-lp-makes-new-251-million-investment-in-iqvia-holdings-inc-iqv-2026-03-17/", "date": "2026-03-17", "summary": "Cinctive Capital Management LP has purchased a new stake of 13,214 shares, valued at approximately $2.51 million, in IQVIA Holdings Inc. Other institutional investors have also adjusted their holdings in IQVIA, with the stock currently having an average \"Buy\" rating and a target price of $229.13 from analysts. IQVIA, a global provider of advanced analytics and contract research services to the life sciences industry, recently reported strong quarterly earnings and revenue that exceeded analyst e", "sentiment_score": 0.511517, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Optionmillionaires", "title": "morning analysts", "text": "", "author": "upbstock", "score": 4, "num_comments": 0, "date": "2026-03-06", "url": "https://reddit.com/r/Optionmillionaires/comments/1rmc2pz/morning_analysts/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Fired from IQVIA. (I'm a CRA in US)", "text": "Now that the dust has settled...\n\nI'm a CRA in the US who was recently fired from IQVIA. It stung a bit because I've never been fired but ultimately I can't help but feel relieved. I was spread across 5 protocols and more than 40 sites, averaging 11 DOS. I had 3 different line managers in 2 years. My most recent LM seemed to have a serious personal bias against me. She was a neurotic Karen with bad lip filler who kissed up to the Director. During a recent meeting with her she told me she wants t", "author": "Pushin_pristine", "score": 170, "num_comments": 48, "date": "2026-03-12", "url": "https://reddit.com/r/clinicalresearch/comments/1rrrimj/fired_from_iqvia_im_a_cra_in_us/", "sentiment": { "label": "negative", "score": -0.557, "confidence": 0.56 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "I Think IQVIA Is Hiring", "text": "From the posts I’ve seen on Reddit, job postings on IQVIA’s website, and LinkedIn posts, I think IQVIA is hiring. \n\nI think IQVIA is poaching sponsors from ICON and I’ve seen a flood of job postings.\n\nOf course, most of them require monitoring experience, but I’m sure they’ll make some exceptions.\n\nI could be dead wrong so please don’t come at me for that, but I just wanted to share.\n\nAlso, I think there’s been an uptick in clinical trials in general, so maybe all CROs/sponsors are hiring (excep", "author": "Working_Row_8455", "score": 27, "num_comments": 53, "date": "2026-03-18", "url": "https://reddit.com/r/clinicalresearch/comments/1rwo4xw/i_think_iqvia_is_hiring/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA vs ICON", "text": "I am an IQVIA Sr CRA that got an offer from ICON for a Sponsor Dedicated Sr CRA position. During the interview process the hiring managers explained that there is a chance for more remote monitoring as the sponsor prefers remote monitoring for their studies. There are no DOS metric. \n\nIQVIA said they cannot match it or give me any additional compensation at all to stay but have been trying to convince me to stay due to the known ICON layoffs. \n\nDo I stay since I’m comfortable with my studies an", "author": "BumbleLemon", "score": 13, "num_comments": 48, "date": "2026-03-26", "url": "https://reddit.com/r/clinicalresearch/comments/1s3xb56/iqvia_vs_icon/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA or Thermo Fisher", "text": "I’m a CRA I at IQVIA in Lilly FSP and was offered a CRA I position at TFS in the GSK FSP. TFS is offering a 5k salary increase and a 10k signing bonus. Very conflicted on what to do. Any thought? ", "author": "NotB3rry", "score": 17, "num_comments": 23, "date": "2026-03-22", "url": "https://reddit.com/r/clinicalresearch/comments/1s0cct4/iqvia_or_thermo_fisher/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA BioTech Layoffs", "text": "Received word from a colleague that several Project Coordinators from IQVIA BioTech were laid off this morning. They were blindsided with an HR ambush during 1:1s with their managers. Anyone know if any other departments and functions were affected? ", "author": "fjn4766", "score": 60, "num_comments": 16, "date": "2026-03-02", "url": "https://reddit.com/r/clinicalresearch/comments/1rj68tf/iqvia_biotech_layoffs/", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA Biotech Phone Interview", "text": "For those who were offered the CRA I position at IQVIA Biotech, how long after the phone interview did you wait for the first round of interviews?", "author": "Extension_Ad6682", "score": 4, "num_comments": 9, "date": "2026-03-27", "url": "https://reddit.com/r/clinicalresearch/comments/1s5jqly/iqvia_biotech_phone_interview/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BPOinPH", "title": "IQVIA hr interview", "text": "I have scheduled hr interview this week, positions I'm applying is Data Management Specialist, any tips po? 😊\n", "author": "Icy_Emphasis_1622", "score": 1, "num_comments": 12, "date": "2026-03-03", "url": "https://reddit.com/r/BPOinPH/comments/1rjlkg1/iqvia_hr_interview/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Iqvia FSP for AZ", "text": "Give me the details! As a CRA how is the work life balance. How is the job? If you currently work there how is it? How is the sponsor? ", "author": "Former-Illustrator97", "score": 5, "num_comments": 9, "date": "2026-03-17", "url": "https://reddit.com/r/clinicalresearch/comments/1rwfa75/iqvia_fsp_for_az/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Return to Iqvia?", "text": "Left Iqvia as a CRA2 a few months ago and joined a small CRO (<6,000 global employees) as a Sr CRA. Getting offered a position back at Iqvia as a Sr CRA. Should I make the switch, salary is a bit higher than current. ", "author": "brownboyham", "score": 10, "num_comments": 5, "date": "2026-03-26", "url": "https://reddit.com/r/clinicalresearch/comments/1s49x1f/return_to_iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "DLM Salaries IQVIA", "text": "Anyone know what the current DLM salaries are in US or Canada at IQVIA? Range? ", "author": "bo0mchikaboom", "score": 10, "num_comments": 5, "date": "2026-03-26", "url": "https://reddit.com/r/clinicalresearch/comments/1s472fg/dlm_salaries_iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA: Tips on how I can position myself for a promotion?", "text": "Hello,\n\nI currently work as a PMA and have been on the job for 3 years now. I have an accumulative experience of over 5 years in Clinical Project Management. \n\nI want a promotion for all the obvious reasons. I would like some advice on how I can best position myself to be considered. In the year-end review my performance was graded mostly 'Exceeds expectations'. \n\nI want to build on this in 2026 and hopefully get a promotion. Any tips?", "author": "1xthovo", "score": 8, "num_comments": 4, "date": "2026-03-28", "url": "https://reddit.com/r/clinicalresearch/comments/1s690j3/iqvia_tips_on_how_i_can_position_myself_for_a/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "IQVIA", "title": "Iqvia", "text": "Hi, I am from preclinical immuno-onlcology research background with ~8yrs of experience in a lab setting. I am trying to transition into a CRA role and having a hard time getting through the interview screening process. I am also on an H1B visa and would require sponsorship/transfer for my next role in clinical research.\n\n1. I would really appreciate any recommendations/suggestions that might help me create a stronger resume which reflects my documentation/SOP writing, understanding of ICH/GCP g", "author": "Difficult_Theme_6920", "score": 0, "num_comments": 2, "date": "2026-03-30", "url": "https://reddit.com/r/IQVIA/comments/1s82c51/iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "dietetics", "title": "Working for IQVIA?", "text": "Anyone work for this company before? Any feedback?", "author": "One_Fan4776", "score": 5, "num_comments": 5, "date": "2026-03-03", "url": "https://reddit.com/r/dietetics/comments/1rk3ylq/working_for_iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "IQVIA Car allowance", "text": "Anyone knows how old/new your personal car should be at IQVIA to get car allowance? For CRA role", "author": "Remote-Meal-9241", "score": 1, "num_comments": 5, "date": "2026-03-06", "url": "https://reddit.com/r/clinicalresearch/comments/1rmd9xa/iqvia_car_allowance/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Online interview with IQVIA", "text": "How can I prepare for an interview with IQVIA?\n\nThe position is Clinical Intern. Are there any specific questions I should review, especially for an online interview?", "author": "bushra2030", "score": 1, "num_comments": 5, "date": "2026-03-06", "url": "https://reddit.com/r/clinicalresearch/comments/1rmawlp/online_interview_with_iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "IQVIA", "title": "referral iqvia cra italia", "text": "quanto contano i referral in questa posizione? perchè ne avrei bisogno \n\ngraaazie", "author": "Lazy-Law8834", "score": 0, "num_comments": 3, "date": "2026-03-19", "url": "https://reddit.com/r/IQVIA/comments/1rxx37m/referral_iqvia_cra_italia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Iqvia", "text": "", "author": "Difficult_Theme_6920", "score": 0, "num_comments": 1, "date": "2026-03-30", "url": "https://reddit.com/r/clinicalresearch/comments/1s82cfn/iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "consultingcareers", "title": "IQVIA R2", "text": "Can anyone who had an R2 interview at IQVIA share what case study they had (feel free to dm)? ", "author": "Small-Anything-5004", "score": 1, "num_comments": 1, "date": "2026-03-22", "url": "https://reddit.com/r/consultingcareers/comments/1s0smjr/iqvia_r2/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Iqvia", "text": "", "author": "Difficult_Theme_6920", "score": 0, "num_comments": 0, "date": "2026-03-30", "url": "https://reddit.com/r/clinicalresearch/comments/1s82ctd/iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BPOinPH", "title": "IQVIA Benefits and Culture", "text": "Hello! Kakatapos ko lang ng final interview and waiting na lang ako sa JO email for Virtual Moderator position. Anyone here who can share about the benefits in IQVIA such as the HMO free dependents, night diff, other allowances, etc. Di ko kase natanong mga to sa interviewer kasi ung manager sa US naginterview saken ng initial and final. \n\nSalamat po sa sasagot! ", "author": "spaghetti-with-rice", "score": 1, "num_comments": 1, "date": "2026-03-20", "url": "https://reddit.com/r/BPOinPH/comments/1ryqowo/iqvia_benefits_and_culture/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "reddit", "subreddit": "tax", "title": "IQVIA tax deduction info", "text": "How does IQVIA deduct tax from salary?\n\nis it on monthly basis or yearly basis?", "author": "rohklr", "score": 2, "num_comments": 0, "date": "2026-03-25", "url": "https://reddit.com/r/tax/comments/1s3fy9s/iqvia_tax_deduction_info/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BPOinPH", "title": "IQVIA Hybrid?", "text": "Hello! \n\nI just wanted to ask if anyone here is currently working at IQVIA as Product Support—what’s the work setup like? Is it hybrid, and how often are you required to go to the office?\n\nThank you!!", "author": "biscuitlia", "score": 2, "num_comments": 0, "date": "2026-03-25", "url": "https://reddit.com/r/BPOinPH/comments/1s34eds/iqvia_hybrid/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BPOinPH", "title": "Iqvia", "text": "To anyone planning to apply sa IQVIA, better not to proceed haha the management and company itself was so good before, i can guarantee work-life balance pero now, it seems to have na they do not care sa employees nila at all. We were required to shift from once a month rto to thrice a month. aside from that, they made new rules about PIP na para kaming robot lol, we're not required to fail even once, they have discussed it in a subtle way naman tho pero di naman kami baliw para di magets hahaha ", "author": "jjngkk", "score": 1, "num_comments": 0, "date": "2026-03-25", "url": "https://reddit.com/r/BPOinPH/comments/1s3i0in/iqvia/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "clinicalresearch", "title": "Astra Zeneca IQVIA FSP CRA Insights", "text": "Hi everyone! I see that there are a lot of reviews from AstraZeneca Onco CRAs sharing that it’s a great FSP, but I wanted to see if anyone has experience as a CRA not on their oncology teams? Any insights? :) ", "author": "ExperienceNo424", "score": 4, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/clinicalresearch/comments/1rz6zek/astra_zeneca_iqvia_fsp_cra_insights/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }